Table 1.2Risk of neutropenic sepsis from differing chemotherapy regimens

Tumour siteRegimenLikelihood of neutropenic sepsis (%)Trial
Breast TAC128.8 Martin, et al., 2005
FEC100-T225 Head, et al., 2008
FAC34.4 Martin, et al., 2005
Lung Carboplatin / Etoposide10-20 Crawford, et al., 2011
Gemcitabine / Cisplatin7 Cardenal, 1999
Colorectal FOLFIRI411 Douillard, et al., 2000
FOLFOX456 Rotheberg, et al., 2003
Gastric / Oesophageal EOX610 Cunningham, et al., 2010
NHL CHOP735Lyman, et al., 2003
Hodgkin disease ABVD82-12% Vakkalanka, Link, 2011
Germ cell BEP9 (including CBOP-BEP)1018 Teoh, et al., 2006
Head and neck TPF119 Vermorken, 2007
1

Docetaxel 75mg/m2, doxorubicin 50mg/m2, cyclophosphamide 500mg/m2 d1 of 21 day cycle

2

Fluorouracil 500mg/m2, epirubucin 100mg/m2, cyclophosphamide 500mg/m2, d1 of 21 day cycle for 3 cycles then docetaxel 100mg/m2 d1 of 21 day cycle for 3 cycles

3

Fluorouracil 500mg/m2, doxorubicin 50mg/m2, cyclophosphamide 500mg/m2 d1 of 21 day cycle

4

Either irinotecan 80mg/m2, fluorouracil infusion (24h) 2300mg/m2, calcium folinate 500mg/m2 d1 weekly OR irinotecan 180mg/m2, fluorouracil 400mg/m2 bolus and 600mg/m2 22 hour infusion and calcium folinate 500mg/m2 d1 of 14 day cycle

5

Oxaliplatin 85mg/m2 d1, leucovarin 200mg/m2, fluorouracil 400mg/m2 bolus and 600mg/m2 22 hour infusion d1 and 2 of 14

6

Epirubicin 50mg/m2, oxaliplatin 130mg/m2 and d1 capecitabine 625mg/m2 bd daily 21 day cycle

7

Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2 d1 and prednisolone 100mg d1-5 of 21 day cycle

8

Doxorubicin 25mg/m2, bleomycin 10,000u, vinblastine 6mg/m2 and dacarbazine 375mg/m2 d1 and 15 of 28 day cycle

9

Bleomycin, etoposide and cisplatin (exact doses not specified from this source)

10

Bleomycin, etoposide, cisplatin, vincristine and carboplatin (exact dose and schedule not specified from this source)

11

Docetaxel 75mg/m2, Cisplatin 75 mg/m2, fluorouracil 750mg/m2, d1 of 21 day cycle

From: 1, Epidemiology and service provision of neutropenic sepsis in England and Wales

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.